Transplantation
MDS Session: Women in Science
Myelodysplastic syndromes (MDS) are a heterogenous group of myeloid disorders characterized by the accumulation of dysplastic cells within the bone…
Date: 17th May 2021
The Transplant Sessions: ASH 2020 highlights
The management of post-transplantation relapse and immune attack is an ongoing battle in patients undergoing bone marrow transplants. The efficacy…
Date: 23rd April 2021
The Lymphoma Sessions: ASH 2020 highlights
The treatment of aggressive lymphomas such as diffuse large B-cell has seen dramatic changes, and with the advent of bispecific…
Date: 23rd April 2021
The Myeloma Sessions: Post-ASH 2020 UK Discussion
The development of immunomodulatory agents and proteasome inhibitors alongside stem cell transplantation and chemotherapy has significantly improved the treatment options…
Date: 19th April 2021
The Post-EBMT VJSessions from VJHemOnc
The 47th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) was held virtually this year and…
Date: 7th April 2021
Post-EBMT highlights in acute myeloid leukemia
Acute myeloid leukemia (AML) is the most common type of adult leukemia, with over 19,500 new cases estimated to be…
Date: 6th April 2021
The Lymphoma Sessions: highlights from ASH 2020
Lymphoma is a collection of cancers which develop in the lymphatic system and affect the lymphocytes. The risk factors for…
Date: 17th March 2021
Updates for the management of MDS from ASH 2020
During the 62nd American Society of Hematology (ASH) 2020 Annual Meeting and Exposition, several abstracts provided important updates for the…
Date: 16th February 2021
The AML Sessions: highlights from ASH 2020
Improved understanding around the pathophysiology and heterogeneity of acute myeloid leukemia (AML) has led to a rapidly evolving treatment paradigm…
Date: 16th February 2021
The MDS Sessions: treating MDS around the world
The epidemiology, diagnosis and treatment of myelodysplastic syndromes (MDS) varies across the globe. In resource-limited countries, the diagnosis of MDS…
Date: 12th February 2021
Advances in the amyloidosis space: Prognostic factors, CAEL-101 immunotherapy and real-world data
Amyloidosis is the name attributed to a group of diseases caused by the extracellular accumulation of amyloid, an abnormal, insoluble…
Date: 5th February 2021
The MDS sessions: lower-risk disease
Myelodysplastic syndromes (MDS) represent a range of disorders characterized by morphologic dysplasia, cytopenias, and a risk of progression to acute…
Date: 7th December 2020